替诺福韦的天真和难治性慢性乙肝的治疗：在沙特阿拉伯一

StephenW

Year : 2015  |  Volume : 21  |  Issue : 5  |  Page : 295-299

Tenofovir in the treatment of naïve and refractory chronic Hepatitis B: A single center experience in Saudi Arabia

Fahad Alsohaibani, Noura Alturaif, Ahmed Abdulshakour, Saad Alghamdi, Alfadel Alshaibani, Hamad Alashgar, Khalid Alkahtani, Ingvar Kagevi
Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Correspondence Address:
Fahad Alsohaibani
Department of Medicine, King Faisal Specialist Hospital and Research Centre, MBC 46 P.O Box 3354, Riyadh 11211
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1319-3767.164189



Background/Aims: Tenofovir disoproxil fumarate (TDF) is a nucleotide analog used in the treatment of chronic hepatitis B (CHB) infection. This study evaluated the efficacy of TDF in achieving undetectable HBV DNA after 48 weeks of treatment in a Saudi cohort of CHB patients. Patients and Methods: This retrospective study included patients treated at a tertiary care center in Saudi Arabia from January 2009 to December 2012. Of the 68 eligible patients, 51 were treatment naïve and 17 were treatment-refractory. Twenty-three patients tested positive for HBeAg. The remaining 45 patients were HBeAg-negative. Results: The mean HBV DNA viral load decreased from 95 million IU/mL at baseline to 263 IU/mL after 48 weeks of treatment (P < 0.001). Overall, 62% of patients achieved a complete virological response (CVR) and 37% a partial virological response (PVR). Respective CVR and PVR rates according to subgroup were: HBeAg-positive (21.7% and 78.3%) and HBeAg-negative (84.4% and 15.6%). At 48 weeks, HBV DNA was undetectable in 66.7% of treatment-naÏve and 53% of treatment-refractory patients (P = 0.3). Seroconversion occurred in 13 (57%) of HBeAg-positive patients. Two (3%) of the HBeAg-negative patients lost HBsAg at follow up. Mean alanine aminotransferase decreased significantly from 134 U/L before treatment to 37 U/L at 48 weeks (P < 0.001). Significant adverse events were not encountered during the study period. Conclusion: Forty-eight weeks of treatment with TDF reduced HBV DNA to undetectable levels in more than half of our patients regardless of whether they were treatment-naïve or refractory. HBeAg-negative (vs positive) patients experienced a better response rate.

StephenW

年份：2015年|体积：21 |第5 |页：295-299

替诺福韦的天真和难治性慢性乙肝的治疗：在沙特阿拉伯一个单中心的经验

法赫德Alsohaibani，Noura酒店Alturaif，艾哈迈德Abdulshakour，萨阿德Alghamdi，Alfadel Alshaibani，哈马德Alashgar，哈立德Alkahtani，英格瓦Kagevi
医药，费萨尔国王专科医院和研究中心，利雅得，沙特部

通讯地址：
法赫德Alsohaibani
医学系，费萨尔国王专科医院和研究中心，MBC 46邮政信箱3354，利雅得11211
沙特阿拉伯
登录访问电子邮件ID

无，利益冲突：资助来源无

DOI：10.4103 / 1319-3767.164189



背景/目的：富马酸替诺福韦酯（TDF）在慢性乙型肝炎（CHB）感染的治疗中使用的核苷酸类似物。这项研究评估TDF的疗效慢性乙型肝炎患者的沙特队列治疗48周后达到检测不到HBV DNA。患者与方法：这项回顾性研究包括在三级医疗中心在沙特阿拉伯自2009年1月治疗的患者，以2012年12月68符合条件的患者中，有51个是初次接受治疗，并有17人难治。 23例患者为HBeAg的药检呈阳性。其余45例患者HBeAg阴性。结果：95百万单位/毫升治疗48周（P <0.001）后的平均HBV DNA病毒载量下降在基线到263 IU / mL的。总体而言，62％的患者达到完全病毒学应答器（CVR）和37％的部分病毒学应答（PVR）。根据分组所属CVR和PVR率分别为：HBeAg阳性（21.7％和78.3％）和HBeAg阴性（84.4％和15.6％）。在第48周时，HBV DNA检测不到治疗天真和治疗难治性患者（P = 0.3）的53％，66.7％。血清转换发生在13 HBeAg阳性患者（57％）。其中两个HBeAg阴性患者（3％）失去了乙肝表面抗原的跟进。平均谷丙转氨酶显著从134 U / L，治疗前48周（P <0.001）下降至37 U / L。显著不良事件在研究期间都没有遇到过。结论：四十八周TDF治疗超过一半的患者降低HBV DNA检测不到的水平，无论他们是否是初治或难治。 HBeAg阴性（VS阳性）的患者经历了更好的响应速度。

lwkais

怎么个意思，看不明白

StephenW

回复 lwkais 的帖子

四十八周TDF治疗, 超过一半的患者的HBV DNA降低到检测不到的水平，无论他们是否是初治或难治。 HBeAg阴性（VS阳性）的患者经历了更好的响应速度。

9病成医

替诺48周后，还有一半的人病毒没有转阴，效果不是很理想啊

lwkais

DNA降低到检测不到的水平，目前的所有抗病毒药物只要不耐药都可以做到，这没什么新意啊